Efficacy of entecavir/IFN alpha sequential therapy for HBeAg-positive chronic active hepatitis B
Not Applicable
Completed
- Conditions
- HBeAg-positive chronic active hepatitis B
- Registration Number
- JPRN-UMIN000000808
- Lead Sponsor
- Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. use of lamivudine or any other antiviral agents for hepatitis B within 3 months before the start of therapy 2. presence of lamivudine-resistant YMDD variants 3. clinical signs of decompensated cirrhosis or liver failure 4. other likely causes of chronic liver disease 5. severe complication (poor renal, cardiac, or respiratory function) 6. women who are possibly pregnant, expectant mothers, and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method